REGN · Regeneron Pharmaceuticals

Biotech behind eye drug Eylea and blockbuster Dupixent

Risiko 4/10 · LOW-MODERATE RISK · two-drug biotech major · $827.72 ▼ 1.87%🤖Von KI geschrieben

Stand der Zahlen: 07.09.2026 · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

• Price $827.72
• Market cap $85.2B
• P/E (ttm) 20.49
• Div yield 0.45%
• 52-wk range $541.00 – $859.34
• Index rank #192 / #50

Wichtigste Risiken

• Eylea erosion from biosimilars and rival eye drugs accelerates (Shareholders) — HIGH
• Profit concentration in Dupixent, shared with partner Sanofi (Shareholders) — MED
• Pipeline readouts fail to replace the maturing franchises (Shareholders) — MED
• US drug-pricing reform squeezes reimbursement (Shareholders) — MED

Fazit

Cheap for a reason and cheap enough anyway — the pipeline news will decide which.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.